Bio Minulus
Loading...Bio Minulus Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
WARNINGS: If pregnant or breast-feeding, ask a health care professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
Do not use if tamper evident seal is broken or missing. Store in a cool, dry place.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
INDICATIONS: For temporary relief of fear of known things, shyness, and timidity.
History
There is currently no drug history available for this drug.
Other Information
There are no additional details available for this product.
Sources
Bio Minulus Manufacturers
-
Apotheca Company
![Bio Minulus (Mimulus,) Liquid [Apotheca Company]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Bio Minulus | Amgen Inc
2.1 Recommended DosageThe recommended subcutaneous dosage of REPATHA in patients with HeFH or patients with primary hyperlipidemia with established clinical atherosclerotic CVD is either 140 mg every 2 weeks OR 420 mg once monthly. When switching dosage regimens, administer the first dose of the new regimen on the next scheduled date of the prior regimen.
The recommended subcutaneous dosage of REPATHA in patients with HoFH is 420 mg once monthly. In patients with HoFH, measure LDL-C levels 4 to 8 weeks after starting REPATHA, since response to therapy will depend on the degree of LDL-receptor function.
If an every 2 week or once monthly dose is missed, instruct the patient to:
Administer REPATHA as soon as possible if there are more than 7 days until the next scheduled dose, or,
Omit the missed dose and administer the next dose according to the original schedule. 2.2 Important Administration Instructions To administer the 420 mg dose, give 3 REPATHA injections consecutively within 30 minutes. Provide proper training to patients and/or caregivers on how to prepare and administer REPATHA prior to use, according to the Instructions for Use, including aseptic technique. Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use REPATHA. Keep REPATHA in the refrigerator. Prior to use, allow REPATHA to warm to room temperature for at least 30 minutes. Do not warm in any other way. Alternatively, for patients and caregivers, REPATHA can be kept at room temperature (up to 25°C (77°F)) in the original carton. However, under these conditions, REPATHA must be used within 30 days [see How Supplied/Storage and Handling (16)]. Visually inspect REPATHA for particles and discoloration prior to administration. REPATHA is a clear to opalescent, colorless to pale yellow solution. Do not use if the solution is cloudy or discolored or contains particles. Administer REPATHA by subcutaneous injection into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated using a single-use prefilled syringe or single-use prefilled autoinjector. Do not co-administer REPATHA with other injectable drugs at the same injection site. Rotate the injection site with each injection.
Login To Your Free Account